Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. develops therapeutics for Alzheimer's disease and metabolic disorders as a clinical-stage biotechnology company. News about IGC Pharma commonly centers on IGC-AD1, its cannabinoid-based lead asset in the CALMA Phase 2 trial for agitation in Alzheimer's dementia, along with pipeline programs such as TGR-63, IGC-1C and IGC-M3 targeting amyloid plaques, tau pathways, neuroinflammation and related neurodegeneration biology.
Company updates also cover the use of artificial intelligence in drug discovery and clinical-trial operations, including the Agentic Harmonization Assistant platform for biomedical data harmonization. Other recurring developments include clinical-site expansion, caregiver and patient-engagement initiatives, psilocybin research authorization in Colombia, patent activity and financial reporting.
IGC Pharma (NYSE American: IGC) announced on January 6, 2026 that its Board approved changing the company fiscal year end from March 31 to December 31, effective December 31, 2025. The company said the alignment with the calendar year is intended to improve clarity, comparability, and accessibility of financial reporting for U.S. investors and to support more consistent communication with U.S. capital markets as clinical and AI programs advance.
As a result, IGC Pharma will file a transition Form 10-K covering the nine-month period from April 1, 2025 through December 31, 2025, and will report on a calendar-year basis beginning in 2026. The company does not expect the change to affect business operations, strategic priorities, or SEC compliance.
IGC Pharma (NYSE American: IGC) announced a registered direct offering of 779,997 shares at $0.30 per share, expected to raise approximately $234,000 in gross proceeds on January 5, 2026. The company said net proceeds will be used for working capital and general corporate purposes, including continued funding of its IGC-AD1 Phase 2 clinical development program for Alzheimer’s disease.
The shares were offered under an effective shelf registration on Form S-3 (File No. 333-276330) declared effective January 8, 2024. Management described the new investors as long-term, strategic supporters who may provide experience and networks to advance IGC’s clinical programs.
IGC Pharma (NYSE American: IGC) announced that the USPTO issued U.S. Patent No. 12,491,200 on December 19, 2025, covering a novel microdose-based cannabinoid treatment for stuttering and Tourette's Syndrome.
The patent protects ultra-low THC dosing, alone or with CBD or other agents, to modulate neural circuits tied to vocal disruptions and tics, and complements IGC's existing neurological pipeline including IGC-AD1 in the CALMA trial for agitation in Alzheimer's disease.
IGC Pharma (NYSE American: IGC) commented on recent federal momentum toward possible Schedule III reclassification for cannabinoids and positioned itself as a focused beneficiary within the FDA-regulated pharmaceutical pathway. The company highlighted its lead candidate, IGC-AD1, currently in a Phase 2 CALMA study for agitation associated with Alzheimer’s disease, and emphasized a long‑horizon strategy built on microdosing, safety, patents, and AI-driven drug development.
IGC outlined potential long-term benefits if policy evolves, including expanded clinical institution participation, more efficient pharma-grade manufacturing and supply chains, and improved engagement from financial institutions and capital markets.
IGC Pharma (NYSE American: IGC) announced that Ascendiant Capital Markets issued an updated coverage report on December 10, 2025, following IGC's Q2 results. Ascendiant raised its price target to $4.75 and said more positive clinical data and program progress in 2025/26 could act as catalysts for the stock.
The company clarified that analyst reports reflect the analysts' views, that IGC is not responsible for analysts' content or timelines, and provided a link to obtain the full Ascendiant report.
IGC Pharma (NYSE:IGC) announced it has reached 65% patient enrollment in the Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s disease as of December 9, 2025. The company said enrollment has accelerated and remains on track for trial completion in early 2026. The release notes a hybrid recruitment approach: 25% of participants were recruited via targeted social-media campaigns and 75% via clinical sites. Interim analyses previously reported by the company showed clinical and statistically significant reductions in agitation. IGC continues to expand U.S. and Canada clinical operations and to focus on data quality and site performance.
IGC Pharma (NYSE:IGC) announced publication of "Caring for a Loved One with Alzheimer's Disease: First Hand Experiences" on December 2, 2025, a caregiver-focused book sponsored by IGC and authored by clinical neuropsychologists including Dr. Juan Carlos Arango-Lasprilla and Dr. Sandra Báez.
The book combines science-based educational chapters (disease progression, diagnosis, treatments, caregiver health, planning) with first-person caregiver stories addressing emotional, behavioral, and social challenges. IGC said the publication aligns with its mission while it advances IGC-AD1 in the Phase 2 CALMA trial for agitation in Alzheimer's dementia and develops AI-driven therapeutic programs.
IGC Pharma (NYSE American: IGC) announced advances in MINT-AD, a Multimodal Interpretable Transformer for Alzheimer’s that uses AI and global longitudinal datasets to identify socioeconomic risk factors tied to cognitive decline. The model was trained on 14 large-scale HRS-based studies spanning the USA, Africa, Mexico, China, Costa Rica, Puerto Rico, Chile, Brazil, England, Thailand, Indonesia, India, and Korea. The initiative targets risk stratification, early detection, and simulation of disease progression under interventions, and complements ongoing IGC-AD1 clinical trials aimed at agitation and potential disease-modifying therapies.
IGC says the work may enable earlier prediction, personalized non-pharmacological interventions, and data-driven public health strategies.
IGC Pharma (NYSE American: IGC) reported Q2 FY2026 results for the quarter ended September 30, 2025, and outlined operational progress.
Key items: Phase 2 CALMA enrollment surpassed 50%; a strategic divestiture of a Vancouver manufacturing facility closed for $2.7 million producing an approximate $1.1 million non-cash profit and eliminating $600,000 in annual expenses; other net income rose 2,407%; R&D spending increased 73% to $1.6 million; revenue declined ~54% to $191,000; net loss was $1.8 million ($0.02/share). The company noted NIA recognition for its AI work and ongoing pipeline advances including IGC-M3 and patent allowance for IGC510.
IGC Pharma (NYSE:IGC) announced that the USPTO granted U.S. Patent No. 12,465,589 on November 11, 2025 for "Methods and Composition for Treating CNS Disorders."
The patent covers the proprietary formulation used in IGC-AD1, the company's lead candidate now in the Phase 2 CALMA trial for agitation in Alzheimer's disease, and claims effects on amyloid-beta, tau phosphorylation, mitochondrial function, and behavioral symptoms including agitation, memory, cognition, anxiety, and sleep disturbances.